Local production and/or delivery of anti-cancer agents by stromal cell precursors

• US 20040076622A1
• Filed: 02/28/2003
• Published: 04/22/2004
• Est. Priority Date: 03/02/2002
• Status: Abandoned Application

• Current Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Inventors: Studeny, Matus, Marini, Frank C., Andreeff, Michael
• Application Number:
  US10/377,276
• Publication Number:
  US 20040076622A1
• Time in Patent Office: Days
• US Class Current: 424/93.21
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 38/212 IFN-alpha
• CPC Class Codes: A61K 38/215 IFN-beta
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2750/14143 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2830/002 inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
• CPC Class Codes: C12N 2830/15 chimeric enhancer/promoter combination
• CPC Class Codes: C12N 2840/203 having an IRES
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)

Abstract

The present invention concerns the use of compositions comprising, and methods for making, genetically modified mesenchymal stem cells to treat subjects with hyperproliferative disorders. Certain embodiments allow local delivery of an agent while avoiding systemic delivery of the agent alone. Stromat precursor cells may be used to produce a biological agent locally at tumor sites. The tumor microenvironment, or other proliferation inducing microenvironment, preferentially promotes the engraftment of stromal precursors as compared to other tissues.

Claims

1. A composition comprising a stromal cell precursor that is genetically modified to produce an anti-cancer agent.

2. The composition of claim 1, wherein said anti-cancer agent is a cytokine, a hormone, an extracellular matrix component, an enzyme, a signaling molecule, an anti-angiogenic polypeptide, or an oncolytic virus.

3. The composition of claim 1, wherein said genetically modified stromal cell precursor produces IFN-α

or IFN-β

.

4. The composition of claim 1, wherein said therapeutic agent is secreted from said genetically modified stromal cell precursor.

5. The composition of claim 1, wherein said therapeutic agent is expressed on a cell surface of said genetically modified stromal cell precursor.

6. The composition of claim 1, further comprising a pharmaceutically acceptable carrier.

7. The composition of claim 1, wherein said stromal cell precursor is genetically modified by genomic integration of an expression cassette.

8. The composition of claim 1, wherein said stromal cell precursor is genetically modified by episomal expression vector.

9. The composition of claim 8, wherein said expression vector is a viral expression vector.

10. An anti-cancer composition comprising a stromal cell precursor engineered to express an anti-cancer gene product, wherein said stromal cell precursor preferentially localizes in an area of an organism undergoing hyperproliferative cell growth.

11. The composition of claim 10, wherein said stromal cell precursors engraft in a tumor.

12. The composition of claim 10, wherein said anti-cancer gene product is toxic when administered intravascularly.

13. The composition of claim 10, wherein said anti-cancer gene product is secreted from said stromal cell precursor.

14. The composition of claim 10, wherein said anti-cancer gene product is expressed on the cell surface of said stromal cell precursor.

15. The composition of claim 10, further comprising a pharmaceutically acceptable carrier.

16. The composition of claim 10, wherein said stromal cell precursor is genetically modified by genomic integration of an expression cassette.

17. The composition of claim 10, wherein said stromal cell precursor is genetically modified by episomal expression vector.

18. The composition of claim 10, wherein said anti-cancer gene product is IFN-α

, IFN-β

, IFN-γ

or a combination thereof.

19. The composition of claim 17, wherein said expression vector is a viral expression vector.

20. A method for treatment of a subject with cancer comprising:

a) isolating stromal cell precursors from a donor;

b) propagating the isolated stromal cell precursors in vitro;

c) genetically modifying one or more of the isolated stromal cell precursors to express a therapeutic agent; and

d) introducing genetically modified stromal cell precursors into said subject.

21. The method of claim 20, wherein said genetically modified stromal cell precursors are introduced by injection.

22. The method of claim 21, wherein said genetically modified stromal cell precursors are introduced by intravascular injection.

23. The method of claim 21, wherein said genetically modified stromal cell precursors are introduced by intratumoral injection.

24. The method of claim 20, wherein said donor is said subject being treated.

25. The method of claim 20, wherein said donor is a heterologous donor.

26. A method for the delivery of a therapeutic agent to a patient comprising introducing a genetically modified stromal cell precursors to the patient.

27. The method of claim 26, wherein said patient is a cancer patient.

28. The method of claim 27, wherein said cancer patient has chronic myelogenous leukemia.

29. The method of claim 27, wherein said cancer patient has melanoma.

30. The method of claim 27, wherein said cancer patient has breast cancer.

31. The method of claim 27, wherein said cancer patient has ovarian cancer.

32. The method of claim 27, wherein said cancer patient has a brain cancer.

33. A method for reducing tumor growth comprising administering genetically modified stromal cell precursors.

34. The method claim 33, wherein said genetically modified stromal cell precursors are administered by injection.

35. The method of claim 34, wherein said injection is intravascular.

36. The method of claim 34, wherein said injection is intratumoral.

37. The method of claim 33, wherein said stromal cell precursors express INF-α

or INF-β

.

38. The method of claim 37, wherein said stromal cell precursors express INF-α

.

39. The method of claim 37, wherein said stromal cell precursors express INF-β

.

40. A method of reducing tumor burden in a patient with cancer comprising administering a genetically modified stromal cell precursors.

41. The method claim 40, wherein said genetically modified stromal cell precursors are administered by injection.

42. The method of claim 41, wherein said injection is intravascular.

43. The method of claim 41, wherein said injection is intratumoral.

44. The method of claim 40, wherein said stromal cell precursors express MNF-α

or INF-β

.

45. The method of claim 44, wherein said stromal cell precursors express INF-α

.

46. The method of claim 44, wherein said stromal cell precursors express INF-β

.

47. A method of treating metastatic cancer comprising administering a genetically modified stromal cell precursors.

48. The method claim 47, wherein said genetically modified stromal cell precursors are administered by injection.

49. The method of claim 48, wherein said injection is intravascular.

50. The method of claim 48, wherein said injection is intratumoral.

51. The method of claim 47, wherein said stromal cell precursors express INF-α

or INF-β

.

52. The method of claim 51, wherein said stromal cell precursors express INF-α

.

53. The method of claim 51, wherein said stromal cell precursors express INF-β

.

54. A method of rendering an inoperable tumor operable comprising administering a genetically modified stromal cell precursors.

55. The method claim 54, wherein said genetically modified stromal cell precursors are administered by injection.

56. The method of claim 55, wherein said injection is intravascular.

57. The method of claim 55, wherein said injection is intratumoral.

58. The method of claim 54, wherein said stromal cell precursors express INF-α

or INF-β

.

59. The method of claim 58, wherein said stromal cell precursors express INF-α

.

60. The method of claim 58, wherein said stromal cell precursors express INF-β

.

61. A method of increasing cancer patient survival comprising administering a genetically modified stromal cell precursors.

62. The method claim 61, wherein said genetically modified stromal cell precursors are administered by injection.

63. The method of claim 62, wherein said injection is intravascular.

64. The method of claim 63, wherein said injection is intratumoral.

65. The method of claim 61, wherein said stromal cell precursors express INF-α

or INF-β

.

66. The method of claim 65, wherein said stromal cell precursors express INF-α

.

67. The method of claim 65, wherein said stromal cell precursors express INF-β

.

68. A method of inhibiting hyperproliferative disease comprising administering a genetically modified stromal cell precursors.

69. The method claim 68, wherein said genetically modified stromal cell precursors are administered by injection.

70. The method of claim 69, wherein said injection is intravascular.

71. The method of claim 69, wherein said injection is intratumoral.

72. The method of claim 68, wherein said stromal cell precursors express INF-α

or INF-β

.

73. The method of claim 72, wherein said stromal cell precursors express INF-α

.

74. The method of claim 72, wherein said stromal cell precursors express INF-β

.

75. A method of engrafling a therapeutic cell in a tumor comprising:

a) isolating stromal cell precursors;

b) propagating the isolated stromal cell precursors in vitro;

c) genetically modifying one or more of the isolated stromal cell precursors to express a therapeutic agent; and

d) administering said genetically modified stromal cell precursors to a subject.

76. The method claim 75, wherein said genetically modified stromal cell precursors are administered by injection.

77. The method of claim 76, wherein said injection is intravascular.

78. The method of claim 77, wherein said injection is intratumoral.

79. The method of claim 75, wherein said stromal cell precursors express INF-α

, INF-β

, or a combination thereof.

80. The method of claim 79, wherein said stromal cell precursors express INF-α

.

81. The method of claim 79, wherein said stromal cell precursors express INF-β

.